Pfizer and Medicus Enter Licensing Deal Worth Up to $1 Billion for Antibody Drug Conjugate
Medicus Pharma announced a licensing agreement with Pfizer worth up to $1 billion. The deal involves the joint development and commercialization of PF-08046031, also known as CD228V, an antibody drug conjugate currently in early-stage clinical trials. Under the terms of the partnership, Medicus will collaborate closely with Pfizer on advancing this therapeutic candidate. This collaboration highlights a strategic move by both companies to leverage their respective strengths and accelerate innovation in oncology treatments.
Topics: drug development licensing agreement pharmaceuticals